Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metastasis Target Validation.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CLIC3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLIC3 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli or Eukaryotic expression. |
View CLIC3 Products |
| Gene Delivery | CLIC3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and transport assays. |
View CLIC3 Products |
| Benchmark Ab | Anti-CLIC3 Recombinant Antibody Sequence-verified positive control for IHC, IP, and neutralization assays. |
View CLIC3 Products |
| Validator | CLIC3 siRNA Set For knockdown verification in functional assays. |
View CLIC3 Products |
| Related Target A | ITGB1 (Integrin beta-1) CLIC3 directly regulates the recycling of active ITGB1 to drive cancer cell invasion. |
View ITGB1 Products |
| Related Target B | CLIC4 Closely related homolog required for selectivity and off-target counter-screening. |
View CLIC4 Products |
| Related Target C | ITGA5 (Integrin alpha-5) Forms heterodimer with ITGB1; trafficking is regulated by CLIC3. |
View ITGA5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular/Membrane Dual State | High-purity recombinant proteins (>95% by SDS-PAGE) with verified theoretical MW for bilayer insertion. |
| CLIC Family Off-target Profiling | Homolog panel (CLIC1, CLIC4) strictly verified by mass spectrometry for counter-screening. |
| Lack of Reliable Cell Models | Lentivirus Premade Particles for stable overexpressing cell line construction. |
| High False Positive Rates | Sequence-specific siRNA sets included for target knockdown validation. |
Live CLIC3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CLIC3 therapeutics is intensifying, with major players shifting focus from traditional intracellular targets to the regulation of endosomal trafficking networks. As first-generation therapies reach the clinic, the next wave of R&D is targeting CLIC3-mediated integrin recycling to block metastasis in aggressive cancers such as pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech | Pancreatic Cancer, Ovarian Cancer | Selectivity Assay (Need CLIC3 vs CLIC1/CLIC4 proteins) |
| RNAi / siRNA | Innovative RNA Biotechs | Metastatic Solid Tumors | Knockdown Validation (Need validated siRNA + Lentivirus controls) |
| Monoclonal Antibodies | Preclinical Stage Biotechs | Tumor Angiogenesis (Secreted CLIC3) | Binding Affinity & Epitope Mapping (Need high-purity recombinant CLIC3) |